

MEETING VENUE

Teatro del Sale

Via dei Macci, 111/r
50122 Firenze FI



Scientific Chairmen

Giacomo Emmi
Benjamin Terrier
Augusto Vaglio

Faculty

Alvise Berti, *Italy*
Alessandra Bettiol, *Italy*
Marco Caminati, *Italy*
Matthew Lawson Coates, *UK*
Paolo Delvino, *Italy*
Allyson Egan, *Ireland*
Giacomo Emmi, *Italy*
Georgina Espigol, *Spain*
Mathieu Groh, *France*
Loïc Guillevin, *France*
Irene Mattioli, *Italy*
Peter Merkel, *USA*
Aladdin Mohammad, *Sweden*
Sara Monti, *Italy*
Thomas Neumann, *Switzerland*
Roberto Padoan, *Italy*
Julie Power, *Ireland*
Xavier Puechal, *France*
Dario Roccatello, *Italy*
Carlo Salvarani, *Italy*
Salman Siddiqui, *UK*
Renato Alberto Sinico, *Italy*
Camille Taillè, *France*
Benjamin Terrier, *France*
Michelangelo Tesi, *Italy*
Francesca Torracca, *Italy*
Augusto Vaglio, *Italy*

Main Sponsor



Organizing Secretariat



Viale dei Mille, 137
50131 Firenze
Email: costanza.calamai@eve-lab.it
Tel. 055 0671000
www.eve-lab.com

5th MEETING OF THE EUROPEAN EGPA STUDY GROUP



June
9th
2023
FLORENCE
Teatro del Sale

EGPA MEETING PROGRAM

FLORENCE

9

FRIDAY
JUNE 9th

8.15 am Welcome and introduction
A. Vaglio, B. Terrier, G. Emmi

FIRST SESSION

Chairmen: *A. Berti, A. Mohammad*

8.30 am BUILDING A EUROPEAN EGPA PATIENT ADVOCACY ORGANIZATION
F. Torracca, president of the Italian EGPA association (APACS)
J. Power, delegate from Vasculitis Ireland

Open discussion

SECOND SESSION

Chairmen: *T. Neumann, C. Salvarani*

9.30 am NON-PHARMACOLOGICAL STUDIES

Lecture:

The pathogenesis of EGPA: an overview

A. Vaglio

Discussion

Ongoing and completed non-pharmacological studies:

SPASMEO: a multicenter European retrospective study on coronary vasospasm and eosinophilia

M. Groh

Epigenetic biomarkers of EGPA: un update

M. Tesi

Eosinophilia-related temporal arteritis

B. Terrier

Epidemiology of EGPA in Europe

G. Emmi

Understanding the tissue immune landscape of EGPA through nasal mucosal associated lymphoid tissue biopsy

M. L. Coates

EGPA biobank

A. Vaglio

Long term follow up of cardiac involvement in EGPA

S. Monti

Overall long-term follow up and damage accrual in EGPA across Europe

A. Mohammad, R. Padoan

Open discussion

THIRD SESSION - morning

Chairmen: *R. A. Sinico, C. Taillè*

11.30 am PHARMACOLOGICAL STUDIES

Lecture:

Should we abandon traditional immunosuppressants in EGPA?

L. Guillevin

Completed studies:

AAV-PRO questionnaire in patients with EGPA initiating mepolizumab

P. Delvino

Benralizumab in EGPA: a multicenter study

A. Bettiol

EGPA onset during biologic treatment for severe asthma

M. Caminati

1.00 pm Lunch

THIRD SESSION - afternoon

Chairmen: *R. A. Sinico, C. Taillè*

2.00 pm PHARMACOLOGICAL STUDIES

Ongoing studies:

Dupilumab in EGPA

B. Terrier

Benralizumab vs Mepolizumab: a European real-life retrospective multicentre study

I. Mattioli

Mepolizumab in EGPA: a long-term follow-up study

G. Emmi

Mepolizumab 300 mg/month in newly diagnosed EGPA patients: a prospective study

R. Padoan

The impact of BMI on the effectiveness of Mepolizumab in EGPA patients

A. Berti

Safety and efficacy of Rituximab in patients with EGPA and renal involvement

D. Roccatello

Mycophenolate mofetil remission induction and maintenance therapy in EGPA: a multi-centre observational study

A. Egan

Open discussion

3.45 pm Coffee break

FOURTH SESSION

Chairmen: *G. Espigol, X. Puechal*

4.00 pm EGPA RECOMMENDATIONS AND UPDATE ON CLINICAL TRIALS

The new guidelines for EGPA

A. Vaglio

The FVSG trials in EGPA: un update

B. Terrier

The VCRC EGPA Longitudinal Study: un update

P. Merkel

Tezepelumab in EGPA

S. Siddiqui

Open discussion

5.45 pm Close

A. Vaglio, B. Terrier, G. Emmi